MedTrace Logo

The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject

NCT05737576 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2024-02-07

No results posted yet for this study

Summary

The objective of the study is to compare the pharmacokinetics and pharmacodynamics between HR011408 and NovoRapid® in healthy subject.

Conditions

Interventions

DRUG

HR011408 injection; NovoRapid®

HR011408 injection, administered subcutaneously in dose 1. NovoRapid®, administered subcutaneously in dose 1.

DRUG

NovoRapid®；HR011408 injection

NovoRapid®, administered subcutaneously in dose 1. HR011408 injection, administered subcutaneously in dose 1.

DRUG

HR011408 injection; NovoRapid®

HR011408 injection, administered subcutaneously in dose 2. NovoRapid®, administered subcutaneously in dose 2.

DRUG

NovoRapid®；HR011408 injection

NovoRapid®, administered subcutaneously in dose 2. HR011408 injection, administered subcutaneously in dose 2.

DRUG

HR011408 injection; NovoRapid®

HR011408 injection, administered subcutaneously in dose 3. NovoRapid®, administered subcutaneously in dose 3.

DRUG

HR011408 injection; NovoRapid®

NovoRapid®, administered subcutaneously in dose 3. HR011408 injection, administered subcutaneously in dose 3.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-20
Primary Completion
2023-10-26
Completion
2023-12-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05737576 on ClinicalTrials.gov